Roivant Sciences Ltd (NASDAQ: ROIV) kicked off on Monday, down -1.28% from the previous trading day, before settling in for the closing price of $11.68. Over the past 52 weeks, ROIV has traded in a range of $8.47-$13.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 493.24%. While this was happening, its average annual earnings per share was recorded -114.15%. With a float of $376.16 million, this company’s outstanding shares have now reached $806.68 million.
Let’s determine the extent of company efficiency that accounts for 908 employees. In terms of profitability, gross margin is 88.72%, operating margin of 3057.91%, and the pretax margin is 2937.2%.
Roivant Sciences Ltd (ROIV) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Roivant Sciences Ltd is 49.13%, while institutional ownership is 61.87%. The most recent insider transaction that took place on Oct 21 ’24, was worth 1,165,000. In this transaction President & COO of this company sold 100,000 shares at a rate of $11.65, taking the stock ownership to the 617,470 shares. Before that another transaction happened on Oct 21 ’24, when Company’s Officer proposed sale 100,000 for $11.65, making the entire transaction worth $1,165,393.
Roivant Sciences Ltd (ROIV) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -114.15% per share during the next fiscal year.
Roivant Sciences Ltd (NASDAQ: ROIV) Trading Performance Indicators
Take a look at Roivant Sciences Ltd’s (ROIV) current performance indicators. Last quarter, stock had a quick ratio of 27.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 54.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.57, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.09 in one year’s time.
Technical Analysis of Roivant Sciences Ltd (ROIV)
Looking closely at Roivant Sciences Ltd (NASDAQ: ROIV), its last 5-days average volume was 3.45 million, which is a drop from its year-to-date volume of 5.87 million. As of the previous 9 days, the stock’s Stochastic %D was 21.69%. Additionally, its Average True Range was 0.27.
During the past 100 days, Roivant Sciences Ltd’s (ROIV) raw stochastic average was set at 50.08%, which indicates a significant increase from 12.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.99% in the past 14 days, which was lower than the 26.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.80, while its 200-day Moving Average is $11.13. However, in the short run, Roivant Sciences Ltd’s stock first resistance to watch stands at $11.65. Second resistance stands at $11.78. The third major resistance level sits at $11.86. If the price goes on to break the first support level at $11.44, it is likely to go to the next support level at $11.36. Should the price break the second support level, the third support level stands at $11.23.
Roivant Sciences Ltd (NASDAQ: ROIV) Key Stats
The company with the Market Capitalisation of 8.62 billion has total of 739,522K Shares Outstanding. Its annual sales at the moment are 124,800 K in contrast with the sum of 4,349 M annual income. Company’s last quarter sales were recorded 55,130 K and last quarter income was 95,300 K.
